IVERIC bio, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) (NCT04435366) | IVERIC bio, Inc. | 2020-06-22 |
Track IVERIC bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.